Researchers at the Spanish National Center for Cardiovascular Research (CNIC) have identified a new target that may open new avenues into pulmonary hypertension (PH) treatment. Their findings were published in Science Advances on Jan. 19, 2024.

Researchers from the Institute for Bioengineering of Catalonia (IBEC) and collaborators have successfully treated bladder tumors in mice using urease-powered nanobots. The testing consisted of the administration of 18F-nanorobots to tumor-bearing mice divided into four groups depending on tumor volumes using a group of non-tumor-bearing mice as control. Importantly, the therapy remained in the bladder with only a very small proportion of radioactivity seen in other organs. The results were published in Nature Nanotechnology on Jan. 15, 2024.

Researchers at Mount Sinai have identified a unique neuron type that could explain vulnerability in Parkinson’s disease and thus help unravel the neuronal complexity of this disorder – hopefully leading to more precise and effective therapies. The findings, published in Science Advances on Jan. 10, 2024, provide new insights into the genetic causes and changes occurring in substantia nigra during PD pathogenesis.

Researchers at Boston Children's Hospital and Harvard Medical School have explored the possibility of using anaplastic lymphoma kinase (ALK) as a target for the application of ALK.CAR T cells to treat neuroblastoma, the most common and deadliest tumor of infancy.

To date, no cardiovascular model has been able to shed light on how and why cardiac congenital disorders start in the human embryo. Researchers from the Institute of Molecular Biotechnology (IMBA) in Vienna have been able to recapitulate cardiogenesis in multi-chamber cardioids, sort of interacting heart chambers intended to dissect how genetic and environmental factors impact human heart development.

At the IDWeek 2023 infectious disease conference, Rachelle Koch, a medical student from the University of Texas Southwestern Medical Center, presented the work done in David Greenberg’s Lab on a new strategy to tackle Pseudomonas aeruginosa infections using D-peptide-conjugated phosphorodiamidate morpholino oligomers (D-PPMOs). P. aeruginosa is an opportunistic pathogen showing a multidrug-resistance (MDR) pattern that is at the root of significant morbidity and mortality, especially in immunocompromised patients with severe chronic lung diseases such as cystic fibrosis.

During the IDWeek conference held in Boston earlier this month, presentations on Climate Change were spread throughout the program. Some talks were on the direct effects of weather on infectious agents. Others discussed what healthcare workers could do to mitigate the effects of climate change, from antibiotic stewardship to decarbonization of day to day operations.

Increasing knowledge of the cancer glycome and the need for new options to overcome resistance to immune checkpoint inhibitors are leading to an expansion of glycoimmunology. Stanford University professor Carolyn Bertozzi demonstrated that cell-surface glycans may be tagged to become targetable glyco-immune checkpoints.

At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena.

In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.